TAK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	1.22M
Gjennomsnittsvolum	1.83M
Markedsverdi	41.33B
EPS	$0 ( 2024-02-01 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0.270 ( 2022-09-29 )
Next Dividend	$0 ( N/A )
P/E	36.58
ATR14	$0.00500 (0.04%)

Volum Korrelasjon

Lang: 0.36 (neutral)

Kort: 1.00 (very strong)

Signal:(76.794) Expect same movement, but be aware

Takeda Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Takeda Pharmaceutical Korrelasjon - Valuta/Råvare

0.45
( neutral )

0.40
( neutral )

0.00
( neutral )

-0.52
( weak negative )

Takeda Pharmaceutical Økonomi

Annual	2023
Omsetning:	$4 027.48B
Bruttogevinst:	$2 783.41B (69.11 %)
EPS:	$204.29

FY	2023
Omsetning:	$4 027.48B
Bruttogevinst:	$2 783.41B (69.11 %)
EPS:	$204.29

FY	2022
Omsetning:	$3 569.01B
Bruttogevinst:	$2 462.16B (68.99 %)
EPS:	$147.14

FY	2021
Omsetning:	$3 197.81B
Bruttogevinst:	$2 203.50B (68.91 %)
EPS:	$120.36

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Takeda Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.76 - low (58.20%) | Divividend Growth Potential Score: 3.01 - Decrease likely (39.79%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.470	2008-09-25
Last Dividend	$0.270	2022-09-29
Next Dividend	$0	N/A
Payout Date	2022-12-12
Next Payout Date	N/A
# dividends	27	--
Total Paid Out	$11.88	--
Avg. Dividend % Per Year	1.27%	--
Score	2.45	--
Div. Sustainability Score	4.76
Div.Growth Potential Score	3.01
Div. Directional Score	3.89	--

Next Divdend (Est)
(2024-08-15)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.45

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2008	$0.470	3.54%
2009	$1.000	6.24%
2010	$0.533	4.02%
2011	$1.135	7.11%
2012	$1.110	7.35%
2013	$0.894	5.57%
2014	$0.822	4.87%
2015	$0.730	4.62%
2016	$0.829	4.27%
2017	$0.798	4.71%
2018	$0.802	3.34%
2019	$0.828	4.92%
2020	$0.850	4.27%
2021	$0.804	4.47%
2022	$0.270	1.96%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0427	1.500	9.15	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0125	1.200	9.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0263	1.500	-0.819	-1.228	[0.1 - 1]
payoutRatioTTM	1.619	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.064	0.800	9.68	7.74	[1 - 3]
quickRatioTTM	0.465	0.800	-1.972	-1.578	[0.8 - 2.5]
cashRatioTTM	0.126	1.500	-0.409	-0.614	[0.2 - 2]
debtRatioTTM	0.328	-1.500	4.53	-6.80	[0 - 0.6]
interestCoverageTTM	1.450	1.000	-0.574	-0.574	[3 - 30]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.692	-1.500	7.23	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.675	1.000	2.08	2.08	[0.2 - 0.8]
operatingProfitMarginTTM	0.0750	1.000	-0.500	-0.500	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.157	1.000	-0.240	-0.240	[0.2 - 2]
assetTurnoverTTM	0.293	0.800	-1.379	-1.103	[0.5 - 2]
Total Score				4.76

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.04	1.000	8.28	0	[1 - 100]
returnOnEquityTTM	0.0263	2.50	-0.526	-1.228	[0.1 - 1.5]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0.0274	1.500	9.31	0	[0 - 0.4]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.619	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.00295	1.500	-3.31	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.175	1.000	8.11	0	[0.1 - 0.5]
Total Score				3.01

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.